REGISTRATION

MRAs in CKD: Lessons from a Scientist, an Investigator, and a Trialist

Steroidal mineralocorticoid receptor antagonists (MRA) have been around for decades and were expected to protect against diabetic kidney disease (DKD), as other blockers of the renin-angiotensin aldosterone system (RAS) did. These benefits were not observed, however, until the development of the non-steroidal MRA, finerenone, which reduced DKD progression in patients on RAS blockade in the FIDELIO study. This webinar reviews cell biology relevant to MRAs and DKD, presents official highlights from the FIDELIO team, and takes an independent dive into the trial and implications for practice.

Learning objectives:

Learn about the mechanisms of DKD and the potential of MRAs
Learn about the outcome of the FIDELIO clinical trial
Understand any implications of FIDELIO’s design and sub-group analyses for clinical practice

Further reading:

Latest Results on FIGARO/FIDELIO Studies

The FIGARO-DKD study was presented last week during the Hot Line session on August 28 at ESC Congress 2021, and simultaneously published in the New England Journal of Medicine. Finerenone reduces the risk of cardiovascular and renal outcomes compared to placebo in patients with type 2 diabetes and mild-to-moderate kidney disease.
Also presented during the Hotline session at ESC Congress 2021 were data from FIDELITY, a prespecified meta-analysis of more than 13,000 patients from the Phase III studies FIGARO-DKD and FIDELIO-DKD. The results demonstrated cardiovascular and renal benefits of finerenone in patients with CKD and T2D.

This webinar kicks off a series aiming at presenting the outcomes of the FIDELIO and FIGARO trials and discussing how their results may impact future clinical practice. Book your calendars already!

The registration links to the next webinars will follow soon.

The webinar either no longer exists or an error has occured.